Spots Global Cancer Trial Database for childhood solid neoplasm

Every month we try and update this database with for childhood solid neoplasm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors	NCT02975882	Childhood Solid... Recurrent Malig... Recurrent Prima... Refractory Mali... Refractory Prim...	Irinotecan Hydr... Laboratory Biom... Pharmacological... Sirolimus Album... Temozolomide	12 Months - 21 Years	Children's Oncology Group
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia	NCT01445080	Blastic Phase Childhood Acute... Childhood Chron... Childhood Solid... Chronic Myeloge... Juvenile Myelom... Philadelphia Ch... Recurrent Child... Recurrent Child... Recurrent Disea...	Laboratory Biom... Pharmacological... Sorafenib Tosyl...	2 Years - 21 Years	National Cancer Institute (NCI)
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer	NCT00898079	Acute Undiffere... Atypical Chroni... Childhood Acute... Childhood Acute... Childhood Chron... Childhood Solid... Chronic Lymphoc... Hairy Cell Leuk... Juvenile Myelom... Mast Cell Leuke... Neoplasm of Unc... Prolymphocytic ... Secondary Acute... T-Cell Large Gr...	Cytology Specim...	- 30 Years	Children's Oncology Group
Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors	NCT01725191	Childhood Solid...	Laboratory Biom... Pharmacological... Tivantinib	13 Months - 21 Years	National Cancer Institute (NCI)
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia	NCT01445080	Blastic Phase Childhood Acute... Childhood Chron... Childhood Solid... Chronic Myeloge... Juvenile Myelom... Philadelphia Ch... Recurrent Child... Recurrent Child... Recurrent Disea...	Laboratory Biom... Pharmacological... Sorafenib Tosyl...	2 Years - 21 Years	National Cancer Institute (NCI)
Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	NCT01606878	Childhood Solid... Recurrent Child... Recurrent Neuro...	Crizotinib Cyclophosphamid... Dexrazoxane Hyd... Doxorubicin Hyd... Laboratory Biom... Pharmacological... Questionnaire A... Topotecan Hydro... Vincristine Sul...	13 Months - 21 Years	Children's Oncology Group
Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1	NCT02775292	Adult Solid Neo... Childhood Solid... Metastatic Neop...	Aldesleukin Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Nivolumab NY-ESO-1 Reacti... NY-ESO-1(157-16... Positron Emissi...	16 Years -	Jonsson Comprehensive Cancer Center
Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1	NCT02775292	Adult Solid Neo... Childhood Solid... Metastatic Neop...	Aldesleukin Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Nivolumab NY-ESO-1 Reacti... NY-ESO-1(157-16... Positron Emissi...	16 Years -	Jonsson Comprehensive Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: